Anika Therapeutics, Inc. ANIK
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.42% | -2.50% | -7.91% | -12.61% | -12.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.42% | -2.50% | -7.91% | -12.61% | -12.33% |
| Cost of Revenue | -10.45% | -39.56% | -33.05% | -30.44% | -24.82% |
| Gross Profit | 25.49% | 55.56% | 25.36% | 8.82% | 1.27% |
| SG&A Expenses | 3.39% | -9.46% | -11.18% | -19.69% | -23.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.85% | -21.50% | -19.34% | -21.81% | -20.28% |
| Operating Income | 99.03% | 91.75% | 65.71% | 62.32% | 57.31% |
| Income Before Tax | 90.04% | 91.77% | 68.58% | 69.68% | 64.88% |
| Income Tax Expenses | -117.52% | -96.29% | -86.91% | -89.16% | -48.49% |
| Earnings from Continuing Operations | 98.20% | 92.39% | 71.53% | 72.96% | 61.22% |
| Earnings from Discontinued Operations | 91.96% | 96.62% | 100.08% | 95.38% | 69.09% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 94.65% | 93.76% | 80.50% | 80.70% | 66.12% |
| EBIT | 99.03% | 91.75% | 65.71% | 62.32% | 57.31% |
| EBITDA | 191.07% | 110.63% | 77.88% | 74.66% | -220.53% |
| EPS Basic | 94.37% | 93.57% | 79.57% | 80.25% | 65.68% |
| Normalized Basic EPS | 116.96% | 98.66% | 68.66% | 64.53% | 64.87% |
| EPS Diluted | 93.83% | 93.28% | 79.31% | 79.88% | 65.54% |
| Normalized Diluted EPS | 115.47% | 98.18% | 68.75% | 64.62% | 65.03% |
| Average Basic Shares Outstanding | -5.44% | -4.23% | -3.24% | -2.60% | -2.20% |
| Average Diluted Shares Outstanding | -4.41% | -3.21% | -2.41% | -1.77% | -2.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |